207 related articles for article (PubMed ID: 32604105)
1. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?
Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105
[TBL] [Abstract][Full Text] [Related]
2. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
England JR; Paluch J; Ballas LK; Jadvar H
Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
Teyateeti A; Khan B; Teyateeti A; Chen B; Bridhikitti J; Pan T; Peng W; Macapinlac HA; Lu Y
Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
7. Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer.
Chaussé G; Abikhzer G; Probst S
Clin Nucl Med; 2018 Apr; 43(4):250-251. PubMed ID: 29465489
[TBL] [Abstract][Full Text] [Related]
8. Effect of hormonal therapy on
Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
[TBL] [Abstract][Full Text] [Related]
9. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases.
Chen B; Macapinlac HA; Lu Y
Clin Nucl Med; 2019 Apr; 44(4):337-338. PubMed ID: 30688749
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
[No Abstract] [Full Text] [Related]
14. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
[TBL] [Abstract][Full Text] [Related]
15. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
16.
Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer.
Hoekstra RJ; Beulens A; Vrijhof EHJEJ; Wyndaele DNJ; Roef M; Brouwer LJM; Somford DM; Sedelaar M; van Basten JA
Nucl Med Commun; 2021 May; 42(5):476-481. PubMed ID: 33323869
[TBL] [Abstract][Full Text] [Related]
18.
Armstrong JM; Martin CR; Dechet C; Morton K; Evans D; Ambrose J; Maughan BL; O'Neil B; Lowrance W
Urol Oncol; 2020 Jul; 38(7):636.e1-636.e6. PubMed ID: 32317221
[TBL] [Abstract][Full Text] [Related]
19. Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences.
Hwang L; Paluch J; Jadvar H; England JR; Desai B; Ballas LK
Clin Nucl Med; 2020 Sep; 45(9):668-671. PubMed ID: 32520496
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
